Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Transcatheter aortic valve implantation (TAVI) in patients with chronic kidney disease (CKD) and concomitant aortic stenosis (AS) has increased with ageing population and the rising burden of atherosclerotic cardiovascular disease. However, data on the trajectory of renal function in patients undergoing TAVI are limited. We investigated the annual changes in the estimated glomerular filtration rate (eGFR) among patients undergoing TAVI and compared the eGFR slopes between patients with and without CKD to evaluate renal prognosis.
This single-center, retrospective cohort study included patients with severe AS who underwent TAVI between June 2016 and July 2024. Patients with a baseline (day of the procedure) eGFR <15 or >100 mL/min/1.73 m2 and those without eGFR measurements ≥30 days following the procedure were excluded. A total of 314 eligible patients were classified into two groups according to baseline eGFR: the non-CKD group with an eGFR of ≥60 mL/min/1.73 m2 and the CKD group with <60 mL/min/1.73 m2. Pre-period was the duration before baseline and post-period was the duration starting after 30 days following the procedure. Linear mixed-effects models with random slopes and intercepts estimated annual changes in eGFR during the pre- and post-periods and included an interaction between time and CKD status. The models were unadjusted and adjusted for baseline age, sex, hemoglobin level, N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, and use of diuretics or mineral corticoid receptor antagonists.
The median follow-up period was 2.0 years. Among the 314 patients, 114 (36.3%) were men, 231 (73.6%) had CKD, the mean (standard deviation) age was 85.2 (4.6) years, and general mean baseline eGFR was 49.9 (17.1) mL/min/1.73 m2. Mean baseline eGFR in the non-CKD and CKD groups was 71.5 (9.1) and 42.6 (12.0) mL/min/1.73 m2, respectively. Hemoglobin, NT-proBNP, and proteinuria differed significantly between groups, whereas other data (e.g., laboratory results, comorbidities) showed no significant differences. In the pre-period, adjusted annual changes in eGFR were −2.35 (95% confidence interval [CI], −3.78 to −0.93; p < 0.001) in the non-CKD group and −2.54 (95% CI, −3.32 to −1.76; p < 0.001) in the CKD group. The group difference in the pre-period was −0.18 (95% CI, −1.80 to 1.44; p = 0.824). In the post-period, changes were −4.03 (95% CI, −6.22 to −1.85; p < 0.001) in the non-CKD group and −1.17 (95% CI, −2.44 to 0.09; p = 0.070) in the CKD group. The group difference in the post-period was 2.86 (95% CI, 0.34 to 5.39; p < 0.05). In the CKD group, the change in post-period improved relative to that in pre-period (1.37 [95% CI, −0.19 to 2.93; p = 0.085]), whereas no such trend was observed in the non-CKD group (−1.68 [95% CI, −4.44 to 1.08; p = 0.231]) (Table 1).
The eGFR decline due to TAVI was attenuated in patients with CKD compared with those without CKD. Renal function in CKD patients may be preserved through hemodynamic improvement following TAVI.
